These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 36835818)

  • 1. Heart Failure Association-International Cardio-Oncology Society Risk Score Validation in HER2-Positive Breast Cancer.
    Cronin M; Crowley A; Davey MG; Ryan P; Abdelshafy M; Elkoumy A; Elzomor H; Arsang-Jang S; Ganly S; Nash P; Crowley J; Sharif F; Simpkin A; Lowery A; Wijns W; Kerin M; Soliman O
    J Clin Med; 2023 Feb; 12(4):. PubMed ID: 36835818
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Anthracycline-induced cardiovascular toxicity: validation of the Heart Failure Association and International Cardio-Oncology Society risk score.
    Rivero-Santana B; Saldaña-García J; Caro-Codón J; Zamora P; Moliner P; Martínez Monzonis A; Zatarain E; Álvarez-Ortega C; Gómez-Prieto P; Pernas S; Rodriguez I; Buño Soto A; Cadenas R; Palacios Ozores P; Pérez Ramírez S; Merino Salvador M; Valbuena S; Fernández Gasso L; Juárez V; Severo A; Terol B; de Soto Álvarez T; Rodríguez O; Brion M; González-Costello J; Canales Albendea M; González-Juanatey JR; Moreno R; López-Sendón J; López-Fernández T
    Eur Heart J; 2024 Aug; ():. PubMed ID: 39106857
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baseline cardio-oncologic risk assessment in breast cancer women and occurrence of cardiovascular events: The HFA/ICOS risk tool in real-world practice.
    Tini G; Cuomo A; Battistoni A; Sarocchi M; Mercurio V; Ameri P; Volpe M; Porto I; Tocchetti CG; Spallarossa P
    Int J Cardiol; 2022 Feb; 349():134-137. PubMed ID: 34848212
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The added value of the HFA/ICOS score in the prediction of chemotherapy-related cardiac dysfunction in breast cancer.
    Di Lisi D; Madaudo C; Faro DC; Rossetto L; Triolo OF; Losi V; Galassi AR; Monte IP; Novo G
    J Cardiovasc Med (Hagerstown); 2024 Mar; 25(3):218-224. PubMed ID: 38305134
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of cardiotoxicity and validation of the Heart Failure Association-International Cardio-Oncology Society risk stratification tool in patients treated with trastuzumab for HER2-positive early breast cancer.
    Battisti NML; Andres MS; Lee KA; Ramalingam S; Nash T; Mappouridou S; Senthivel N; Asavisanu K; Obeid M; Tripodaki ES; Angelis V; Fleming E; Goode EF; John S; Rosen SD; Allen M; Stanway S; Lyon AR; Ring A
    Breast Cancer Res Treat; 2021 Jul; 188(1):149-163. PubMed ID: 33818652
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular adverse events and prognosis in patients with haematologic malignancies and breast cancer receiving anticancer agents: Kurume-CREO Registry insights.
    Shibata T; Nohara S; Morikawa N; Shibao K; Ito S; Shibata R; Toh U; Nagafuji K; Fukami K; Fukumoto Y
    Eur J Prev Cardiol; 2023 Dec; 30(18):1941-1949. PubMed ID: 37352112
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The new HFA/ICOS risk assessment tool to identify patients with chronic myeloid leukaemia at high risk of cardiotoxicity.
    Di Lisi D; Madaudo C; Alagna G; Santoro M; Rossetto L; Siragusa S; Novo G
    ESC Heart Fail; 2022 Jun; 9(3):1914-1919. PubMed ID: 35355425
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC).
    Čelutkienė J; Pudil R; López-Fernández T; Grapsa J; Nihoyannopoulos P; Bergler-Klein J; Cohen-Solal A; Farmakis D; Tocchetti CG; von Haehling S; Barberis V; Flachskampf FA; Čeponienė I; Haegler-Laube E; Suter T; Lapinskas T; Prasad S; de Boer RA; Wechalekar K; Anker MS; Iakobishvili Z; Bucciarelli-Ducci C; Schulz-Menger J; Cosyns B; Gaemperli O; Belenkov Y; Hulot JS; Galderisi M; Lancellotti P; Bax J; Marwick TH; Chioncel O; Jaarsma T; Mullens W; Piepoli M; Thum T; Heymans S; Mueller C; Moura B; Ruschitzka F; Zamorano JL; Rosano G; Coats AJS; Asteggiano R; Seferovic P; Edvardsen T; Lyon AR
    Eur J Heart Fail; 2020 Sep; 22(9):1504-1524. PubMed ID: 32621569
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology.
    Pudil R; Mueller C; Čelutkienė J; Henriksen PA; Lenihan D; Dent S; Barac A; Stanway S; Moslehi J; Suter TM; Ky B; Štěrba M; Cardinale D; Cohen-Solal A; Tocchetti CG; Farmakis D; Bergler-Klein J; Anker MS; Von Haehling S; Belenkov Y; Iakobishvili Z; Maack C; Ciardiello F; Ruschitzka F; Coats AJS; Seferovic P; Lainscak M; Piepoli MF; Chioncel O; Bax J; Hulot JS; Skouri H; Hägler-Laube ES; Asteggiano R; Fernandez TL; de Boer RA; Lyon AR
    Eur J Heart Fail; 2020 Nov; 22(11):1966-1983. PubMed ID: 33006257
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of Risk Prediction Models to Identify Cancer Therapeutics Related Cardiac Dysfunction in Women with HER2+ Breast Cancer.
    Suntheralingam S; Fan CS; Calvillo-Argüelles O; Abdel-Qadir H; Amir E; Thavendiranathan P
    J Clin Med; 2022 Feb; 11(3):. PubMed ID: 35160296
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Personalized Decision Making in Early Stage Breast Cancer: Applying Clinical Prediction Models for Anthracycline Cardiotoxicity and Breast Cancer Mortality Demonstrates Substantial Heterogeneity of Benefit-Harm Trade-off.
    Upshaw JN; Ruthazer R; Miller KD; Parsons SK; Erban JK; O'Neill AM; Demissei B; Sledge G; Wagner L; Ky B; Kent DM
    Clin Breast Cancer; 2019 Aug; 19(4):259-267.e1. PubMed ID: 31175052
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Framingham risk score underestimates the risk of cardiovascular events in the HER2-positive breast cancer population.
    Law W; Johnson C; Rushton M; Dent S
    Curr Oncol; 2017 Oct; 24(5):e348-e353. PubMed ID: 29089804
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Trastuzumab-induced cardiotoxicity: testing a clinical risk score in a real-world cardio-oncology population.
    Rushton M; Johnson C; Dent S
    Curr Oncol; 2017 Jun; 24(3):176-180. PubMed ID: 28680277
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Deceleration capacity of heart rate predicts trastuzumab-related cardiotoxicity in patients with HER2-positive breast cancer: A prospective observational study.
    Feng Y; Qin Z; Yang Z
    J Clin Pharm Ther; 2021 Feb; 46(1):93-98. PubMed ID: 32975332
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Trastuzumab-induced cardiotoxicity: a review of clinical risk factors, pharmacologic prevention, and cardiotoxicity of other HER2-directed therapies.
    Dempsey N; Rosenthal A; Dabas N; Kropotova Y; Lippman M; Bishopric NH
    Breast Cancer Res Treat; 2021 Jul; 188(1):21-36. PubMed ID: 34115243
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An artificial intelligence approach for predicting cardiotoxicity in breast cancer patients receiving anthracycline.
    Chang WT; Liu CF; Feng YH; Liao CT; Wang JJ; Chen ZC; Lee HC; Shih JY
    Arch Toxicol; 2022 Oct; 96(10):2731-2737. PubMed ID: 35876889
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of heart failure risk assessment tools among cancer survivors.
    Soh CH; Marwick TH
    Cardiooncology; 2024 Oct; 10(1):67. PubMed ID: 39394611
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Racial disparities in the rate of cardiotoxicity of HER2-targeted therapies among women with early breast cancer.
    Litvak A; Batukbhai B; Russell SD; Tsai HL; Rosner GL; Jeter SC; Armstrong D; Emens LA; Fetting J; Wolff AC; Silhy R; Stearns V; Connolly RM
    Cancer; 2018 May; 124(9):1904-1911. PubMed ID: 29381193
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cardiac Safety of Dual Anti-HER2 Therapy in the Neoadjuvant Setting for Treatment of HER2-Positive Breast Cancer.
    Yu AF; Singh JC; Wang R; Liu JE; Eaton A; Oeffinger KC; Steingart RM; Hudis CA; Dang CT
    Oncologist; 2017 Jun; 22(6):642-647. PubMed ID: 28341761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cardiac safety analysis of anti-HER2-targeted therapy in early breast cancer.
    Zhang L; Wang Y; Meng W; Zhao W; Tong Z
    Sci Rep; 2022 Aug; 12(1):14312. PubMed ID: 35995984
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.